Nautilus Biotechnology, Inc. (NAUT)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. This filer's financial year end could not be read from its revenue history, so quarters are labelled by the calendar. Amounts in USD.

Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Net Income TTM

-75M -50M -25M 0 25M 50M 75M Q2 '21: -28.5M Q3 '21: -39M Q4 '21: -50.3M Q1 '22: -57.7M Q2 '22: -61.6M Q3 '22: -61.2M Q4 '22: -57.9M Q1 '23: -57.1M Q2 '23: -58.2M Q3 '23: -60.1M Q4 '23: -63.7M Q1 '24: -67.4M Q2 '24: -69.6M Q3 '24: -70.2M Q4 '24: -70.8M Q1 '25: -68.7M Q2 '25: -65.7M Q3 '25: -62.8M Q4 '25: -59M Q1 '26: -57.1M Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25 Q1 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-75M -50M -25M 0 25M 50M 75M Q2 '21: -15.1M Q3 '21: -28.8M Q4 '21: -39.2M Q1 '22: -45.3M Q2 '22: -50.6M Q3 '22: -45.9M Q4 '22: -45.8M Q1 '23: -46M Q2 '23: -46M Q3 '23: -48.2M Q4 '23: -51.7M Q1 '24: -55.5M Q2 '24: -57.4M Q3 '24: -58.7M Q4 '24: -59.1M Q1 '25: -56.8M Q2 '25: -54.7M Q3 '25: -52.6M Q4 '25: -50.7M Q1 '26: -49.9M Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25 Q1 '26

Free Cash Flow TTM

-75M -50M -25M 0 25M 50M 75M Q2 '21: -16.7M Q3 '21: -30.4M Q4 '21: -41.5M Q1 '22: -47.6M Q2 '22: -52.9M Q3 '22: -49M Q4 '22: -48.1M Q1 '23: -48.5M Q2 '23: -48.4M Q3 '23: -50.4M Q4 '23: -54.2M Q1 '24: -57.9M Q2 '24: -59.8M Q3 '24: -61M Q4 '24: -61.3M Q1 '25: -58.5M Q2 '25: -56.3M Q3 '25: -53.9M Q4 '25: -52M Q1 '26: -51.4M Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25 Q1 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 50M 100M 150M Q2 '20: 28.2M Q3 '20: 30M Q1 '21: 33M Q2 '21: 55.1M Q3 '21: 124.1M Q1 '22: 124.4M Q2 '22: 124.5M Q3 '22: 124.7M Q1 '23: 124.6M Q2 '23: 124.6M Q3 '23: 124.9M Q1 '24: 125.1M Q2 '24: 125.3M Q3 '24: 125.5M Q1 '25: 126.1M Q2 '25: 126.2M Q3 '25: 126.3M Q1 '26: 126.6M Q1 '21 Q1 '22 Q1 '23 Q1 '24 Q1 '25 Q1 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-0.90 -0.60 -0.30 0.00 0.30 0.60 0.90 Q2 '21: -0.75 Q3 '21: -0.74 Q4 '21: -0.69 Q1 '22: -0.57 Q2 '22: -0.50 Q3 '22: -0.49 Q4 '22: -0.46 Q1 '23: -0.45 Q2 '23: -0.46 Q3 '23: -0.48 Q4 '23: -0.52 Q1 '24: -0.55 Q2 '24: -0.56 Q3 '24: -0.56 Q4 '24: -0.56 Q1 '25: -0.54 Q2 '25: -0.52 Q3 '25: -0.50 Q4 '25: -0.47 Q1 '26: -0.46 Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25 Q1 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.